News

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...
HealthDay on MSN6d
Adults Diagnosed With Type 1 Diabetes Face Heart Health Issues, Risk Of Early Death
Key Takeaways People who develop type 1 diabetes in adulthood have a higher risk of heart disease and death from any ...